- Home
- EE vs LENZ Comparison
EE vs LENZ Comparison
Compare EE & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EE
- LENZ
- Stock Information
- Founded
- EE 2003
- LENZ 2019
- Country
- EE United States
- LENZ United States
- Employees
- EE N/A
- LENZ N/A
- Industry
- EE Oil/Gas Transmission
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- EE Utilities
- LENZ Health Care
- Exchange
- EE Nasdaq
- LENZ Nasdaq
- Market Cap
- EE 914.5M
- LENZ 819.1M
- IPO Year
- EE 2022
- LENZ 2021
- Fundamental
- Price
- EE $28.79
- LENZ $30.86
- Analyst Decision
- EE Hold
- LENZ Strong Buy
- Analyst Count
- EE 7
- LENZ 5
- Target Price
- EE $32.29
- LENZ $41.80
- AVG Volume (30 Days)
- EE 435.0K
- LENZ 360.9K
- Earning Date
- EE 08-06-2025
- LENZ 05-07-2025
- Dividend Yield
- EE 0.84%
- LENZ N/A
- EPS Growth
- EE 37.63
- LENZ N/A
- EPS
- EE 1.53
- LENZ N/A
- Revenue
- EE $966,414,000.00
- LENZ N/A
- Revenue This Year
- EE $34.48
- LENZ N/A
- Revenue Next Year
- EE $14.93
- LENZ $544.79
- P/E Ratio
- EE $18.79
- LENZ N/A
- Revenue Growth
- EE N/A
- LENZ N/A
- 52 Week Low
- EE $17.54
- LENZ $16.54
- 52 Week High
- EE $32.99
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- EE 45.46
- LENZ 57.40
- Support Level
- EE $27.78
- LENZ $28.80
- Resistance Level
- EE $29.98
- LENZ $31.45
- Average True Range (ATR)
- EE 0.86
- LENZ 1.64
- MACD
- EE -0.21
- LENZ 0.01
- Stochastic Oscillator
- EE 29.19
- LENZ 71.78
About EE Excelerate Energy Inc.
Excelerate Energy Inc offers LNG solutions, providing integrated services along the LNG value chain. It offers a full range of regasification services, from FSRUs to infrastructure development, to LNG and natural gas supply. Its business spans the globe, with a regional presence in 11 countries and an operational presence in Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.